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High-risk human papillomaviruses (HR-HPVs) are the causative agents for the onset of several epithelial 
cancers in humans. The deregulated expression of the viral oncoproteins E6 and E7 is the driving force 
sustaining the progression of malignant transformation in pre-neoplastic lesions. Targeting the viral 
E6 oncoprotein through inhibitory compounds can counteract the survival of cancer cells due to the 
reactivation of p53-mediated pathways and represents an intriguing strategy to treat HPV-associated 
neoplasias. Here, we describe the development of a quantitative and easy-to-perform assay to 
monitor the E6-mediated degradation of p53 in living cells to be used for small-molecule testing. This 
assay allows to unbiasedly determine whether a compound can protect p53 from the E6-mediated 
degradation in cells, through a simple 3-step protocol. We validated the assay by testing two small 
molecules, SAHA and RITA, reported to impair the E6-mediated p53 degradation. Interestingly, we 
observed that only SAHA efficiently rescued p53, while RITA could not provide the same degree of 
protection. The possibility to specifically and quantitatively monitor the ability of a selected compound 
to rescue p53 in a cellular context through our LumiFluo assay could represent an important step 
towards the successful development of anti-HPV drugs.
Papillomaviruses (PVs) are small DNA viruses that can infect a wide range of mammals, including humans, and 
cause distinctive hyperproliferative lesions of the skin1. About 200 different viral genotypes are known to infect 
humans and a subset of these viruses, such as HPV16, HPV18, HPV31, HPV33, and HPV45, are classified as 
high-risk human papillomaviruses (HR-HPVs) due to their causative role in the development of several epithelial 
cancers, such as cervical, anogenital and some forms of oropharyngeal cancer2. An important clinical issue for the 
treatment of HPV-related diseases is the absence of specific anti-HPV drugs, and the development of a therapeu-
tic vaccine remains an unmet medical need3. Thus, specific anti-HPV treatments are still globally required for the 
multitude of patients already suffering for HPV-induced cancers and for those already infected and at a high risk 
of developing HPV-associated carcinomas.
The ability of HPV to sustain epidermal neoplasias depends on the expression of the viral oncogenes E6 and 
E7, which are the driving forces of keratinocyte hyperproliferation and, at a later stage, cancer progression4. E6 
and E7 are small regulatory proteins important for efficient viral replication, which exert their functions through 
protein-protein interactions (PPIs) exclusively5. However, when the expression of E6 and E7 becomes unregu-
lated, usually as a result of the integration of viral DNA into the host genome, their activities can efficiently induce 
malignant cell transformation by perturbing several signalling pathways involved in cell-cycle control, adhesion 
and differentiation6.
E6 is a very small cysteine-rich protein whose physiological role is to keep the infected cell in an S-phase-like 
state, cooperating with E7 for efficient cellular hijacking7. High-risk E6 proteins target p53 for proteasome-mediated 
degradation, while E7 can inhibit the activity of pRb, thus forcing the cell to continuously proliferate and accumulate 
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somatic mutations8. E6 possesses a multifaceted inhibitory activity against p53, acting directly against the protein 
as well as against other cellular factors that normally lead to the activation of p53, such as p300 and ADA39–11. In 
addition, E6 can bind several other cellular proteins to induce their degradation through the cellular proteasome 
machinery, such as procaspase 8, Bak, Scribble and MAGI-112–15. The viral E6 oncogene undergoes massive splicing 
events, producing several truncated isoforms in addition to the full-length protein, but only the latter mediates the 
degradation of p5316–18. Mechanistically, full-length high-risk E6 proteins can efficiently induce p53 degradation 
through the direct association with both p53 and the cellular ubiquitin ligase E6AP, to form a trimeric complex that 
leads to p53 ubiquitination and degradation19.
The intimate addiction of cancer cells to the sustained activity of E6 represents an advantage for the devel-
opment of anti-cancer drugs, since perturbing E6 activities can restore the intracellular levels of active p53 and 
reactivate p53-mediated pathways, leading to oncogene-induced senescence and eventually apoptosis of cancer 
cells20. Many research groups have already addressed their attention to the development of an anti-E6 compound 
through different approaches21–25. Blocking the formation of the trimeric complex among E6, E6AP and p53 
through a small-molecule compound represents a novel intriguing strategy to inhibit the E6-mediated degrada-
tion of p53 and to counteract the progression of HPV-associated cancers. Indeed, increasing successful examples 
of small-molecule PPI inhibitors, including candidate anticancer drugs, have been reported, thus highlighting the 
potential of targeting PPIs as a novel chemotherapeutic strategy26–28. However, for issues related to the structure, 
size and physico-chemical characteristics of E6, the development of a powerful anti-E6 compound interfering 
with crucial PPIs has proven to be a difficult task over the years. In addition, a major limit was represented by the 
lack of simple biological assays able to specifically and quantitatively evaluate the inhibitory activity of test com-
pounds against the E6-mediated p53 degradation in a cellular context. To overcome this drawback, we developed 
a luminescence/fluorescence-based (LumiFluo) assay to quantitatively monitor the E6-mediated degradation of 
p53 in living cells to be used for small-molecule compound testing.
Results
Selection of the appropriate reporter system to monitor the E6-mediated degradation of p53. 
To measure the degradation of p53 by HR-HPV E6 oncoprotein, we chose H1299 cells as the candidate cell line 
for the purpose of this work. These cells appeared to be a suitable cellular reporter system for three reasons: (i) 
they are a p53−/− cancer cell line wherein the expression of the endogenous p53 is abolished due to a homozygous 
deletion in the TP53 gene; (ii) H1299 cells are epithelial cells devoid of any HPV sequence; and (iii) they are easily 
transfectable. To monitor the intracellular levels of the exogenous p53, cells were transiently transfected with 
pcDNA3-Rluc-p53 which encodes a fusion protein wherein Renilla luciferase (Rluc) is fused at the N-terminal 
end of p53. We first assessed the viability of transfected cells following the expression of Rluc-p53. H1299 cells 
were seeded in a 24-well plate, transfected with increasing amounts of pcDNA3-Rluc-p53 plasmid, or untrans-
fected as a control, and reseeded in a 96-well plate. At 24 hours post-reseeding, cell viability was determined by 
the MTT assay. No significant reduction in the viability of transfected cells was observed independently from the 
amount of pcDNA3-Rluc-p53 used for transfection (Fig. 1). However, we observed changes in cell morphology 
from cobblestone-like to round-shaped cells in samples transfected with amounts of pcDNA3-Rluc-p53 higher 
than 50 ng (data not shown). Thus, we set this quantity as the threshold for pcDNA3-Rluc-p53 and subsequent 
transfections were scaled accordingly. In addition, in order to adapt our reporter system to direct luminometric 
measurements, in following experiments transfected cells were reseeded in 96-well white plates. To normalise 
for the number of cells plated upon reseeding and for transfection efficiency, cells were cotransfected with a plas-
mid expressing eGFP under the control of the cellular EF1α promoter and luminescent signals were normalised 
against fluorescence intensities. This approach allows to work with intact, living cells, avoiding the common step 
of cell lysis used for other normalisation procedures (e.g., normalisation with Firefly luciferase) since celentera-
zine (Rluc substrate) is a cell-permeable molecule and eGFP only requires excitation.
Figure 1. Effect of the expression of Rluc-p53 on the viability of H1299 cells. Cell viability was measured by the 
MTT assay following the transfection of increasing amounts of pcDNA3-Rluc-p53 plasmid into H1299 cells. 
Transfections were performed in 24-well plates and at 24 hours post-transfection cells were reseeded in a 96-
well clear plate for viability determination. The control was represented by untransfected cells.
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Effect of cell density on the emission of Rluc-p53. Several studies have reported the influence of 
cell density on the steady-state levels of p5329–31. High numbers of cell-cell contacts, which recapitulate the 
high-density cell culture conditions, were shown to down-regulate the intracellular levels of p53, likely in an 
Mdm2-dependent manner32. Indeed, when transiently transfected H1299 cells were reseeded at low density 
in 96-well white plates, the relative emission of Rluc-p53 was substantially higher when compared to its emis-
sion in dense culture (Fig. 2a). In addition, we monitored the emission of Rluc-p53 over the course of 72 hours 
post-reseeding in 96-well white plates. As a control, we transiently transfected H1299 cells with a recombi-
nant construct expressing Renilla luciferase fused at the N-terminal end of HPV16 E6 (Rluc-E6) in order to 
compare the expression and intracellular accumulation of the exogenous p53 and E6 proteins by means of the 
time-dependent emission of the Rluc moiety. Strikingly, while the emission levels of Rluc-E6 were substan-
tially higher after 24 hours (which roughly correspond to 16 hours of active cell proliferation), as justified by 
the increase in cell number, the emission of Rluc-p53 never increased but rather progressively decreased over 
the course of time, even during the initial phase of active cell proliferation (i.e., within the initial 32 hours 
post-reseeding) (Fig. 2b). The absence of a peak in the time-dependent emission curve of Rluc-p53 suggested 
that the highest intracellular level of Rluc-p53 is maintained only during the first 20–24 hours post-reseeding 
(approximately corresponding to 12–16 hours of active cell proliferation), i.e., when the number of cell-cell con-
tacts is very low. Indeed, when transiently transfected H1299 cells were plated at different densities, the highest 
average emission of Rluc-p53 per cell was detected in sparse cultures, only when the cells were spatially separated 
from each other (Fig. 2c). On the contrary, the average emission per cell of Rluc-E6 was unaffected by the number 
of cell-cell contacts and slightly decreased only in very dense culture conditions, when cells are characterised by 
low protein synthesis and metabolism. Importantly, our results agree with a previous report indicating that the 
highest intracellular accumulation of ectopically expressed p53 in H1299 cells is achieved in low-density cell 
culture conditions32.
HPV16 E6 efficiently promotes Rluc-p53 degradation. In order to detect the E6-mediated deg-
radation of p53 in a cellular context, we performed the assay by cotransfecting H1299 cells with a HPV16 
E6-expressing plasmid. High-risk E6 oncoproteins mediate the ubiquitination and degradation of p53 through 
the formation of a heterotrimeric complex that involves the direct binding between E6, p53 and the cellular ubiq-
uitin ligase E6AP19. In order to avoid any steric hindrance caused by the addition of tags, which could result in 
an impairment of p53 degradation, untagged HPV16 E6 was chosen for the purpose of this assay. To monitor the 
relative decrease in the emission of Rluc-p53, as a result of its degradation mediated by the viral E6 oncoprotein, 
two batches of H1299 cells were transfected in parallel with pcDNA3.1-EF-1α-GFP and pcDNA3-Rluc-p53 along 
with either p513-E6 or p513 empty vector, as schematically represented in Fig. 3. After overnight incubation, 
transfected cells were trypsinised, counted and reseeded in 96-well white plates. Initially, two cell densities were 
tested, i.e., 3 × 103 cells/well (low-density condition) and 3 × 104 cells/well (high-density condition). The next 
day, luminescent signals were measured and normalised against the fluorescence of eGFP. The emission signals of 
cells cotransfected with p513-E6 were then compared to those of cells cotransfected with empty vector. Indeed, 
the expression of wild-type HPV16 E6 reduced the emission of Rluc-p53, although not dramatically, but only 
in H1299 cells reseeded at low density (Fig. 4a). Thus, in keeping with our findings on the density-dependent 
Figure 2. Cell density-dependent regulation of Rluc-p53. (a) Different accumulation of Rluc-p53 within H1299 
cells cotransfected with pcDNA3-Rluc-p53 and pcDNA3.1-EF-1α-GFP and reseeded in a 96-well white plate at 
high density (3 × 104 cells/well) or low density (3 × 103 cells/well) (**p < 0.01). (b) H1299 cells were transfected 
with pcDNA3-Rluc-p53 or pcDNA3-Rluc-E6, then the next day cells were reseeded at low density (3 × 103 cells/
well) in 96-well white plates. Rluc emissions were monitored over the course of 72 hours post-reseeding, until 
cells reached confluence. The first measurement was performed at 8 hours post-reseeding in 96-well white plates 
and was set as 100%. Subsequent measurements were performed every 12 hours. A representative picture of 
the cell monolayer at each time point is shown (*p < 0.05, ****p < 0.0001 of cells transfected with pcDNA3-
Rluc-E6 versus pcDNA3-Rluc-p53-transfected samples). (c) H1299 cells were transfected as in (b) and reseeded 
in 96-well white plates at different densities. At 24 hours post-reseeding, Rluc emissions were measured and cells 
were subsequently trypsinised and counted in duplicate (***p < 0.001).
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regulation of p53 levels (Fig. 2), these results indicated that the degradation of ectopically expressed p53 mediated 
by HR-HPV E6 oncoprotein in H1299 cells can be efficiently detected only in low-density cell culture conditions.
High-risk E6 oncoproteins are translated from a bicistronic mRNA that produces a pool of different proteins, 
including E7 and several truncated isoforms of E6 (E6*I, E6*II, E6^E7) resulting from mRNA splicing16. Several 
studies showed the inability of these truncated isoforms to efficiently induce the degradation of p53, but their 
expression levels, in particular that of E6*I, equal that of the full-length protein, limiting the degradation activity 
of E6 through direct binding and modulation17,18. Indeed, when we introduced a silent point mutation in the 
splicing donor site of the E6 gene (E6DM), which abrogates the expression of the smaller isoforms in favour of the 
full-length protein, the decrease in the emission of Rluc-p53 observed upon coexpression with E6 was markedly 
enhanced in H1299 cells plated at low density (Fig. 4b).
Next, to test the specificity of the assay, we assayed mutants of HPV16 E6 (E6DM F47R and E6DM F47R/Y43E) 
that were reported to possess a reduced ability to induce the degradation of p53 due to one or two amino acid sub-
stitutions in the p53-binding interface of E619,33. As expected, the ability of E6DM F47R and E6DM F47R/Y43E to 
induce a decrease in the emission of Rluc-p53 was significantly impaired as compared to the wild-type full-length 
E6DM protein (Fig. 4c, lower panel). These results were confirmed by Western blot analysis, as we observed a 
strong reduction of the intracellular levels of Rluc-p53 in H1299 cells cotransfected with p513-E6DM vector, while 
E6DM F47R and E6DM F47R/Y43E could not significantly degrade Rluc-p53 (Fig. 4c, upper panel), in agreement 
with Rluc measurements. Furthermore, we tested whether the transient cotransfection of a plasmid expressing 
E6AP could further enhance the degradation of Rluc-p53 induced by E6DM. Interestingly, the cotransfection of 
pcDNA3-E6AP did not increase the rate of degradation of Rluc-p53, suggesting that the overexpression of E6AP 
is dispensable for the productive degradation of Rluc-p53 in this experimental setting (Fig. 4c, lower panel). The 
activity of E6DM was also tested against Rluc, as a way to determine the specificity of the degradation activity 
towards the p53 moiety rather than the tagged luciferase. As expected, no significant reduction in the emission 
of Rluc was detected (Fig. 4c).
Finally, in order to demonstrate the feasibility of using this assay for high-throughput screenings, we cal-
culated the Z′-factor. To this end, we concomitantly cotransfected three batches of H1299 cells with plasmids 
encoding Rluc-p53 and eGFP along with p513-E6DM, p513-E6DM F47R/Y43E, or p513 empty vector, respectively. 
Transfected cells were then re-seeded in 96-well white plates and the assay was performed as described above. 
The population of cells cotransfected with the p513-E6DM plasmid represented the negative control (highest rate 
of Rluc-p53 degradation), while cells cotransfected with the p513-E6DM F47R/Y43E plasmid represented the 
positive controls (lowest rate of Rluc-p53 degradation). We calculated a Z′-factor of 0.71, thus demonstrating an 
overall good reproducibility and the possibility to employ this assay for high-throughput screening campaigns.
Assay validation using known anti-cervical cancer drugs. In order to demonstrate the ability 
of the LumiFluo assay to identify compounds capable of protecting p53 from the degradation mediated by 
E6, we selected two small molecules that were shown to impair the E6-mediated degradation of p53 in a cel-
lular context, namely Vorinostat (SAHA) and the p53-targeting compound RITA. These two small molecules 
were reported to rescue p53 levels in cervical cancer cells, albeit through different molecular mechanisms34–36. 
Prior to dose-response analyses, in order to investigate whether SAHA and RITA might affect cell viability in 
a p53-independent manner, we assessed the cytotoxic effects of these two compounds in untransfected H1299 
cells by the MTT assay. Both SAHA and RITA did not significantly affect the viability of H1299 cells at any con-
centration tested up to 50 μM (Fig. 5a). Then, H1299 cells were transiently cotransfected with plasmids encoding 
Rluc-p53 and eGFP along with p513-E6DM or p513 empty vector as previously described and treated with SAHA 
and RITA for 24 hours. In order to account for any possible off-target effect induced by compound treatment 
that might affect the intracellular levels of Rluc-p53 (e.g., general upregulation/downregulation of transcription, 
Figure 3. Schematic representation of the experimental procedure. The first day, two batches of H1299 cells 
are concomitantly transfected with plasmids encoding Rluc-p53 and eGFP along with a plasmid encoding 
HPV16 E6 or with empty vector. The second day, cells from both batches are reseeded in 96-well white plates at 
low density (3 × 103 cells/well) as described in the text. In experiments testing candidate inhibitors, at 8 hours 
post-reseeding test compounds are added to both Batch 1 and Batch 2 samples. At day three, fluorimetric and 
luminometric measurements are performed. The RLU/FU ratio of cells cotransfected with empty vector (Batch 
1) is set as 100% and related to the RLU/FU ratio of cells cotransfected with the E6-expressing plasmid (Batch 2) 
in order to calculate the ratio of Rluc-p53 degradation mediated by E6.
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Figure 4. Rluc-p53 is actively degraded by full-length HPV16 E6 in low-density cell culture conditions.  
(a) H1299 cells were cotransfected with pcDNA3-Rluc-p53 and pcDNA3.1-EF-1α-GFP plasmids along with 
p513-E6 or with p513 empty vector and reseeded in a 96-well white plate at high density (HD) or low density 
(LD) for fluorimetric and luminometric analysis (****p < 0.0001). (b) H1299 cells were transfected as in (a) in 
the presence of p513-E6, p513-E6DM or p513 empty vector and reseeded at low density in a 96-well white plate 
(**p < 0.01). (c) Upper panel: Western blot analysis of H1299 cells cotransfected with pcDNA3.1-EF-1α-GFP 
and pcDNA3-Rluc-p53 plasmids in the presence of p513 empty vector (1), p513-E6DM (2), p513-E6DM and 
pcDNA3-E6AP (3), p513-E6DM F47R (4) or p513-E6DM F47R/Y43E (5). β-actin was used as a loading control; 
s.e., short exposure; l.e., long exposure. Lower panel: relative RLU/FU ratios of H1299 cells transfected as 
described in the upper panel (from 1 to 5) and reseeded at low density in a 96-well white plate. As a specificity 
control, H1299 cells were cotransfected with pcDNA3.1-EF-1α-GFP and pcDNA3-Rluc plasmids along with 
p513-E6DM or with p513 empty vector (right columns). The RLU/FU ratios of cells cotransfected with empty 
vector were set as 100% in every experiment (***p < 0.001, ****p < 0.0001).
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Figure 5. SAHA, but not RITA, efficiently rescues Rluc-p53 from the degradation induced by HPV16 E6.  
(a) Cytotoxic effects of SAHA and RITA in untransfected H1299 cells. The control was represented by untreated 
cells. (b) Dose-response analysis of the rescue of Rluc-p53 in transfected H1299 cells following treatment with 
increasing concentrations of SAHA and RITA for 24 hours. The black line in the graph of SAHA-mediated 
rescue of Rluc-p53 represents the sigmoidal Four Parameter Logistic (4PL) regression curve while dotted 
lines indicate the 95% confidence interval of the model. The dashed line in the graph of RITA-mediated 
rescue of Rluc-p53 indicates the maximum average rescue obtained after treatment with concentrations of 
RITA ≥ 2.5 μM. (c) Dose-dependent effect of SAHA and RITA on the intracellular levels of Rluc-p53 in H1299 
cells cotransfected with p513 empty vector. The average RLU of DMSO-treated cells (no compound) was set as 
100% in every experiment (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 of compound-treated samples 
versus the DMSO-treated control).
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translation or cell metabolism), we treated both H1299 cells cotransfected with p513-E6DM and cells cotransfected 
with p513 empty vector. The RLU/FU ratio of compound-treated E6-expressing cells was then compared against 
that of cells not expressing E6DM treated with the same compound concentration, as a way to specifically measure 
the rescue of Rluc-p53 from the degradation activity of E6. The rate of degradation of Rluc-p53 mediated by E6 
measured in treated cells (Δtrd) was then compared to the rate of degradation measured in untreated controls 
(Δunt). To quantitatively measure the rescue of Rluc-p53 induced by SAHA and RITA, a dose-response analysis 
was performed over a wide range of concentrations to obtain compounds’ IC50 values. Taking into account the 
available data reported in the literature34,36, SAHA was tested in a range of concentrations from 0.2 μM to 10 μM, 
and RITA from 0.5 μM to 15 μM. Interestingly, SAHA successfully inhibited the E6-mediated p53 degradation 
with an IC50 value of 1.79 ± 0.50 μM (Fig. 5b), without affecting the intracellular accumulation of neither E6, 
nor of E6AP (Supplementary Fig. 1). Unexpectedly, RITA was unable to rescue Rluc-p53 from the degradation 
induced by E6 in a dose-dependent manner (Fig. 5b). In particular, we observed that treatment with RITA at 
concentrations ≤2.5 μM induced a dose-dependent rescue of Rluc-p53 as previously reported34, albeit weakly. 
However, when cells were treated with RITA at concentrations above 2.5 μM, the rescue of Rluc-p53 settled at 
a constant value of approximately 20%, suggesting that RITA could not efficiently protect Rluc-p53 from the 
E6-mediated degradation in a dose-dependent manner, preventing the possibility to estimate an IC50 value by 
this assay (Fig. 5b). Nevertheless, we observed that RITA treatment in H1299 cells cotransfected with p513 empty 
vector induced a dose-dependent increase of the intracellular levels of Rluc-p53, indicating that RITA can indeed 
stabilise and upregulate p53 in the absence of E6 (Fig. 5c). Conversely, we observed that treatment with SAHA in 
H1299 cells cotransfected with p513 empty vector induced a dose-dependent decrease of the intracellular levels 
of Rluc-p53, in line with previous reports indicating that SAHA generally affects translation, reducing protein 
synthesis37–39.
Discussion
HPV-associated cancers possess the unique characteristic of being intimately addicted to the continuous activity 
of the major viral oncoproteins E6 and E7, and unlike many other solid tumors, they retain wild-type p53 and 
pRb40. Impairing the functions of E6 through an inhibitory small-molecule compound could have profound 
effects on the survival of cancer cells due to the reactivation of p53-mediated pathways and thus represents a 
fascinating strategy for the treatment of HPV-associated neoplasias41,42. However, the successful development 
of anti-HPV drugs has been so far hampered also by the lack of specific and quantitative bioassays capable of 
assessing the inhibitory activity of candidate compounds against E6 functions in a cellular context. Indeed, the 
molecular assays so far available in the field of anti-HPV drug discovery were mostly restricted to in vitro experi-
ments, such ELISAs, pull-down assays, and p53 degradation assays using in vitro translated p53 protein, which are 
all cell-free systems and do not allow any reliable prediction on the activity of test compounds in the cell23,24,43,44. 
Indeed, such an experimental approach often leads to false positive results, i.e., compounds active in vitro that are 
less active or even completely inactive in cell-based systems. Previously, the monitoring of compound-induced 
inhibition of the E6-mediated degradation of p53 in cells was almost exclusively performed through western blot-
ting, detecting the eventual accumulation of p53 in HPV-positive cells (i.e. HeLa, CaSki, and SiHa) following cell 
treatment, harvest, lysis and analysis of cellular lysates. Undoubtedly, this approach is poorly feasible during the 
initial phases of drug discovery, when a high number of compounds have to be tested. In addition, the eventual 
upregulation of the endogenous p53 in HPV-positive cells could be a result of indirect mechanisms and off-target 
effects induced by compound treatment, such as an induction of p53 due to genotoxic stress or general changes 
in gene transcription and translation, rather than a specific direct inhibition of the E6-mediated p53 degradation. 
Although Mesplède and colleagues previously reported a similar strategy to monitor the degradation of p53 by 
E6 proteins of different HPV genotypes45,46, they never used such an approach for testing inhibitory compounds. 
Thus, taking advantage of a pre-existing experimental approach, we report the development and validation of a 
luminescence/fluorescence-based (LumiFluo) cellular assay that specifically monitors the HPV E6-mediated deg-
radation of p53 in living cells and can be employed to quantitatively test the ability of candidate small molecules 
to protect p53 from the degradation activity of E6.
In the assay development, the absence of endogenous p53 represented a major feature in the choice of the 
cell line to be used, as well as the absence of endogenously expressed HPV genes; thus, we chose the H1299 
cell line for the purpose of this assay. Conversely, other groups have preferred the use of C33A cells instead of 
H1299 cells to monitor the E6-mediated Rluc-p53 degradation45–47. However, C33A cells express high levels of 
endogenous p53 due to an Arg to Cys amino acid substitution at position 273 which makes the protein inactive 
and highly expressed. Such a high intracellular accumulation could represent a drawback for the purpose of this 
assay, since the endogenous mutated p53 of C33A cells was shown to be still efficiently bound and degraded by 
E633, thus possibly introducing a bias in the determination of compounds’ IC50 values in the presence of ectopi-
cally expressed Rluc-p53. Noteworthy, control experiments showed that the ectopic expression of HPV16 E6 in 
C33A cells resulted in the concomitant degradation of both endogenous p53 and ectopically expressed Rluc-p53 
(Supplementary Fig. 2). These results also indicated that the experimental approach of this assay indeed reflects 
the biological context of HPV-induced tumours, wherein the endogenous expression of E6 induces the dramatic 
reduction of p53 levels.
A major innovative feature of this assay is the correlation between the density-dependent regulation of p53 
and its degradation mediated by E6, which is hardly detectable if the experiment is performed in high-density cell 
culture conditions (Fig. 4a). To our knowledge, this was never addressed in any study dealing with anti-HPV drug 
discovery before and uncovers a new important methodological aspect for the successful development of anti-E6 
compounds. Interestingly, C33A cells tend to massively detach from the surface when kept in culture, and thus 
we speculate this might be the reason why others have preferred the use of those cells to monitor the E6-mediated 
degradation of p53, since C33A cells hardly reach confluence.
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A third important feature of our LumiFluo assay is the possibility to finely tune the selection of small mole-
cules that directly impair the degradation of p53 induced by E6, because off-target effects are subtracted during 
data analysis. Indeed, off-target effects can represent a major issue in the field of drug discovery, particularly when 
using cell-based assays, because selected compounds can induce undesired effects through unpredicted molecu-
lar mechanisms (such as general nonspecific effects on cellular transcription, metabolism, protein synthesis and 
turnover), thus introducing a bias. In our experimental setting we can avoid such biases by concomitantly treating 
both cells cotransfected with the E6-encoding plasmid and cells cotransfected with empty vector and then cal-
culating the rate of Rluc-p53 degradation in treated samples to be related to the rate of Rluc-p53 degradation in 
untreated controls. This approach strengthens the potency of this assay to unbiasedly determine the ability of a 
compound to specifically protect p53 from the E6-mediated degradation independently of other indirect effects 
that might impact on the intracellular accumulation of Rluc-p53.
In order to validate the ability of this assay to specifically identify compounds capable of impairing the 
E6-mediated degradation of p53, we tested two small molecules (SAHA and RITA) that were reported to rescue 
p53 from the degradation induced by E6 in cervical cancer cells. SAHA is an FDA-approved histone deacetylase 
inhibitor (HDACi) that was shown to impair p53 degradation and downregulate E6 and E7 protein levels in 
cervical cancer cells36,48. Its activity leads to an increase in p53 acetylation, a mechanism known to stabilise and 
enhance p53 transactivation activity, resulting in the accumulation of its intracellular levels35. RITA is a p53 
agonist compound that was shown to directly bind p53, inducing a conformational change that prevents its inter-
action with Mdm2 and E6AP, the latter of which is indispensable for the degradation of p53 mediated by E634,49. 
However, an increasing body of evidence successively suggested that the main mechanism of action of RITA may 
be the induction of DNA damage that leads to the accumulation of p53 levels, rather than a direct binding of RITA 
to p5350,51. By applying our assay, we confirmed that SAHA directly protects p53 from the degradation induced 
by HPV16 E6 in a dose-dependent manner, while RITA is unable to provide a dose-dependent rescue of p53 at 
concentrations higher than 2.5 μM (Fig. 5b). Importantly, our results are in agreement with previous reports 
indicating that hyperacetylated p53, which accumulates following treatment with a HDACi, can no longer be 
degraded by E648, while whether RITA binds to p53 is still debated51,52. Nevertheless, we argue that the partial res-
cue of p53 induced by RITA could recapitulate the effect observed by Zhao and colleagues in HPV-positive can-
cer cells34. Furthermore, we observed that the IC50 value that we determined for SAHA (1.79 ± 0.50 μM) is very 
close to the concentration that He and colleagues determined to inhibit HDAC activity in HeLa cells (2.5 μM)36. 
Finally, the possibility to analyse the effects of compound treatment on the intracellular levels of Rluc-p53 in the 
absence of E6 could additionally serve as a way to determine whether a compound can influence the intracellular 
accumulation of Rluc-p53. Indeed, we observed that SAHA downregulates the intracellular levels of Rluc-p53 in 
a dose-dependent manner, an effect that can be ascribed to the previously reported propensity of SAHA to gener-
ally impair protein synthesis37–39. RITA, instead, was capable of inducing a dose-dependent increase of Rluc-p53 
intracellular levels, up to a 2.5-fold increase when cells were exposed to a RITA concentration of 15 μM (Fig. 5c). 
This observation is in line with the notion that RITA activity converges on p53 accumulation and transactiva-
tion49, albeit our results suggest that RITA is unable to provide a direct specific protection from the degradation 
mediated by E6.
In conclusion, we developed a simple, sensitive, and quantitative cell-based assay that measures the degra-
dation of p53 mediated by the HR-HPV E6 oncoprotein in living cells to be used for small-molecule compound 
testing. Most importantly, by this assay we can specifically determine the ability of a small molecule to inhibit 
the E6-mediated degradation of p53 in a cellular context. Although we tested only two compounds for assay 
validation, our assay could be easily scaled up to test higher numbers of compounds and possibly also amenable 
to automation. In addition, the approach described proposes a cell-based strategy that could be potentially also 
exploited for the identification of compounds that act, through different mechanisms, as general p53 agonists. 
Thus, our LumiFluo assay can represent a new useful biological tool in the field of anti-HPV drug discovery, serv-
ing as a platform for the development of new therapeutic agents for the treatment of HPV-associated neoplasias.
Methods
Plasmid construction and mutagenesis. pcDNA3-Rluc-p53 and pcDNA3-Rluc-E6 plasmids were gen-
erated by the Gateway® cloning system (Thermo Fisher Scientific). Genes encoding wild-type human p53 and 
HPV16 E6 were cloned into a Gateway® entry vector (pDONR207) using BP Clonase (Thermo Fisher Scientific) 
according to manufacturer’s protocol. Sequence-verified clones were used to transfer p53 and HPV16 E6 sequences 
into a Rluc-expressing Gateway® destination vector using LR Clonase (Thermo Fisher Scientific) according to 
manufacturer’s protocol. Final constructs consisted of full-length wild-type p53 or E6 fused at the C-terminal 
end of Rluc. The p513-E6 and pcDNA3-E6AP plasmids were a kind gift of Dr. Lawrence Banks (ICGEB, Trieste, 
Italy). The p513 empty vector was constructed by removing the E6 sequence with BamHI and NotI restriction 
enzymes and subsequently filling and removing 5′ and 3′ overhangs, respectively, using Klenow DNA Polymerase 
(NE BioLabs) for blunt-end ligation. Mutations in the HPV16 E6 gene were introduced by the QuikChange® 
Site-Directed mutagenesis system (Stratagene) according to manufacturer’s protocol. The HPV16 E6 splice donor 
site was mutated from GAGGTA to GAAGTA to create the splicing-defective E6 mutant (E6DM), as previously 
described53. The p53 degradation-defective E6 mutants were created by substituting Phe47 and Tyr43 into Arg and 
Glu, respectively, as reported by Zanier et al.33. pcDNA3.1-EF-1α-GFP was previously reported54.
Cell culture and transfection. The non-small-cell lung carcinoma H1299 cell line was grown in Dulbecco’s mod-
ified Eagle medium (DMEM, Thermo Fisher Scientific), supplemented with 10% foetal bovine serum and 1% penicil-
lin/streptomycin (Thermo Fisher Scientific). Transfections were performed with Lipofectamine 3000 (Thermo Fisher 
Scientific) according to manufacturer’s protocol with a constant Lipofectamine-DNA ratio of 2:1 (µl/µg).
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Chemical compounds. RITA was purchased from Cayman Chemical, while SAHA from Sigma-Aldrich. 
Both compounds were dissolved in DMSO and stock solutions were stored at −20 °C.
Cell viability assay. Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide (MTT) method, as previously reported55. To evaluate the viability of H1299 cells transfected with 
pcDNA3-Rluc-p53, cells were reseeded in quadruplicate in a 96-well clear plate and cell viability was measured at 
24 hours post-reseeding. To evaluate compounds cytotoxicity, 3 × 103 H1299 cells were seeded in a 96-well clear 
plate and treated the next day with scalar dilutions of test compounds in complete medium. Cell viability was then 
measured 24 hours post-treatment.
Western Blot analysis. At 24 hours post-transfection, H1299 cells were collected and lysed in RIPA buffer 
(50 mM Tris, 150 mM NaCl, 1% NP-40, 0.1% SDS) supplemented with Halt Protease Inhibitor Cocktail (Thermo 
Fisher Scientific). Cellular lysates were separated by SDS-PAGE, transferred onto polyvinylidene difluoride 
(PVDF) membranes and analysed by Western blotting. Anti-p53 (DO-1, 1:4,000), anti-E6AP (E-4, 1:500) and 
anti-HPV16 E6 (C-19, 1:100) primary antibodies were from Santa Cruz, while anti-β-actin (A5441, 1:8,000) was 
from Sigma-Aldrich. Horseradish peroxidase-conjugated goat anti-mouse (sc-2055, 1:2,000) and rabbit anti-goat 
(AP106P, 1:2,000) secondary antibodies were from Santa Cruz and Millipore, respectively.
LumiFluo assay and data analysis. Approximately 1.5 × 105 H1299 cells were seeded in a 6-well plate 
and after at least 8 hours to allow proper cell attachment, were transfected as described above. Two batches of 
cells were concomitantly cotransfected with pcDNA3.1-EF-1α-GFP and pcDNA3-Rluc-p53 along with either 
the E6-expressing plasmid or p513 empty vector with a constant eGFP/Rluc-p53/E6 ratio of 10:2:1. The next 
day, transfected cells were trypsinised, counted and reseeded in quadruplicate at 3 × 103 cells/well (low-density 
condition) in 96-well white plates using phenol red-free medium (Thermo Fisher Scientific). After at least 8 hours 
post-reseeding to allow proper cell attachment, test compounds were added in complete phenol red-free medium 
both to cells cotransfected with the p513-E6DM plasmid and to cells cotransfected with p513 empty vector. 
Controls were represented by cells cotransfected with pcDNA3.1-EF-1α-GFP and pcDNA3-Rluc-p53 along with 
the E6-expressing plasmid or empty vector treated with DMSO at the same concentration of compound-treated 
cells. At 24 hours post-treatment, data collection was performed by first measuring eGFP emission and subse-
quently Rluc luminescence. Cells were washed with phosphate buffered saline (PBS) and exposed at an excitation 
wavelength of 485 nm, measuring eGFP emission at 535 nm, integrated over 0.1 s using a VICTOR X2 Multilabel 
Plate Reader (PerkinElmer). Luminometric analysis was performed by removing PBS and adding 30 µl/well of 
benzyl-coelenterazine (P.j.k. GmbH) at a final concentration of 5 µM in PBS, measuring the emission signal at 
460 nm, integrated over 2 s at 3 minutes after substrate addition. The rate of Rluc-p53 degradation was calculated 
as follows:
Δ = − + −–RLU FU(( / ) (RLU/FU) )/(RLU/FU) (1)E6 E6 E6
where (RLU/FU)E6− represents the average luminescent signal, normalised over the fluorescence of eGFP, of cells 
cotransfected with the p513 empty vector, and (RLU/FU)E6+ represents the average luminescent signal, normal-
ised over the fluorescence of eGFP, of E6-expressing cells. To calculate the percentage of rescue (R) of Rluc-p53 
upon compound treatment, the rate of Rluc-p53 degradation in treated cells (Δtrd) was related to the rate of deg-
radation in control cells treated with DMSO (Δunt) as follows:
= − Δ Δ ∗R (1 ( / )) 100 (2)trd unt
Statistical analysis. Data were analysed with unpaired Student t test or one-way analysis of variance 
(ANOVA) and IC50 values were calculated by four parameter logistic (4PL) non-linear regression using GraphPad 
Prism 6 (GraphPad Software Inc.). Values were presented as mean ± SEM of at least three independent experi-
ments. Statistical significance was calculated with a p value < 0.05. To test assay reproducibility, we performed the 
LumiFluo assay with 48 replicates of positive and negative controls (24 for each control group), with each replicate 
composed of a triplicate of cells seeded in 96-well white plates. Z′-factor was calculated using the equation previ-
ously described by Zhang and colleagues56.
Data availability. All data generated or analysed during this study are included in this published article.
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